Negative transcriptional control of ERBB2 gene by MBP-1 and HDAC1: Diagnostic implications in breast cancer

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Contino, Flavia ^a   Mazzarella, Claudia ^a   Ferro, Arianna ^a   Lo Presti, Mariavera ^a,c   Roz, Elena ^c   Lupo, Carmelo ^c   Perconti, Giovanni ^b   Giallongo, Agata ^b   Feo, Salvatore ^a,b  

^a UNIVERSITY OF PALERMO   (Italy)

^b CNR   (Italy)

^c LA MADDALENA CANCER CENTER   (Italy)

Author keywords

Breast cancer; ERBB2; Histone Deacetylase; MBP 1; Transcriptional regulation

Indexed keywords

BINDING PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HISTONE DEACETYLASE 1; HISTONE H4; MYC PROMOTER BINDING PROTEIN 1; MYC PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER GROWTH; CHROMATIN IMMUNOPRECIPITATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; ERBB2 GENE; GENE CONTROL; GENETIC TRANSFECTION; HISTONE ACETYLATION; HUMAN; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PROMOTER REGION; PROTEIN BINDING; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN TARGETING; PROTEIN TRANSPORT; REPORTER GENE; TRANSCRIPTION REGULATION;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HISTONE DEACETYLASE 1; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM PROTEINS; PROMOTER REGIONS, GENETIC; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84873959605     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-81     Document Type: Article

References (43)

1. Hynes NE, MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 2009, 21(2):177-184. 10.1016/j.ceb.2008.12.010, 19208461.
2. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 2000, 14(19):2501-2514. 10.1101/gad.836800, 316970, 11018017.
3. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005, 5(5):341-354. 10.1038/nrc1609, 15864276.
4. Neve RM, Sutterluty H, Pullen N, Lane HA, Daly JM, Krek W, Hynes NE. Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells. Oncogene 2000, 19(13):1647-1656. 10.1038/sj.onc.1203470, 10763821.
5. Hynes NE, Stoelzle T. Key signalling nodes in mammary gland development and cancer: Myc. Breast Cancer Res 2009, 11(5):210. 10.1186/bcr2406, 2790850, 19849814.
6. Ray R, Miller DM. Cloning and characterization of a human c-myc promoter-binding protein. Mol Cell Biol 1991, 11(4):2154-2161. 359903, 2005901.
7. Chaudhary D, Miller DM. The c-myc promoter binding protein (MBP-1) and TBP bind simultaneously in the minor groove of the c-myc P2 promoter. Biochemistry 1995, 34(10):3438-3445. 10.1021/bi00010a036, 7880838.
8. Subramanian A, Miller DM. Structural analysis of alpha-enolase. Mapping the functional domains involved in down-regulation of the c-myc protooncogene. J Biol Chem 2000, 275(8):5958-5965. 10.1074/jbc.275.8.5958, 10681589.
9. Feo S, Arcuri D, Piddini E, Passantino R, Giallongo A. ENO1 gene product binds to the c-myc promoter and acts as a transcriptional repressor: relationship with Myc promoter-binding protein 1 (MBP-1). FEBS Lett 2000, 473(1):47-52. 10.1016/S0014-5793(00)01494-0, 10802057.
10. Lung J, Liu KJ, Chang JY, Leu SJ, Shih NY. MBP-1 is efficiently encoded by an alternative transcript of the ENO1 gene but post-translationally regulated by proteasome-dependent protein turnover. FEBS J 2010, 277(20):4308-4321. 10.1111/j.1742-4658.2010.07819.x, 20849415.
11. Ray RB, Steele R, Seftor E, Hendrix M. Human breast carcinoma cells transfected with the gene encoding a c-myc promoter-binding protein (MBP-1) inhibits tumors in nude mice. Cancer Res 1995, 55(17):3747-3751.
12. Ejeskar K, Krona C, Caren H, Zaibak F, Li L, Martinsson T, Ioannou PA. Introduction of in vitro transcribed ENO1 mRNA into neuroblastoma cells induces cell death. BMC Cancer 2005, 5:161. 10.1186/1471-2407-5-161, 1327688, 16359544.
13. Ghosh AK, Steele R, Ryerse J, Ray RB. Tumor-suppressive effects of MBP-1 in non-small cell lung cancer cells. Cancer Res 2006, 66(24):11907-11912. 10.1158/0008-5472.CAN-06-2754, 17178888.
14. Pal P, Kanaujiya JK, Lochab S, Tripathi SB, Bhatt ML, Singh PK, Sanyal S, Trivedi AK. 2-D gel electrophoresis-based proteomic analysis reveals that ormeloxifen induces G0-G1 growth arrest and ERK-mediated apoptosis in chronic myeloid leukemia cells K562. Proteomics 2011, 11(8):1517-1529. 10.1002/pmic.201000720, 21360677.
15. Trojanowicz B, Winkler A, Hammje K, Chen Z, Sekulla C, Glanz D, Schmutzler C, Mentrup B, Hombach-Klonisch S, Klonisch T, et al. Retinoic acid-mediated down-regulation of ENO1/MBP-1 gene products caused decreased invasiveness of the follicular thyroid carcinoma cell lines. J Mol Endocrinol 2009, 42(3):249-260.
16. Hsu KW, Hsieh RH, Wu CW, Chi CW, Lee YH, Kuo ML, Wu KJ, Yeh TS. MBP-1 suppresses growth and metastasis of gastric cancer cells through COX-2. Mol Biol Cell 2009, 20(24):5127-5137. 10.1091/mbc.E09-05-0386, 2793290, 19846662.
17. Ghosh AK, Majumder M, Steele R, White RA, Ray RB. A novel 16-kilodalton cellular protein physically interacts with and antagonizes the functional activity of c-myc promoter-binding protein 1. Mol Cell Biol 2001, 21(2):655-662. 10.1128/MCB.21.2.655-662.2001, 86643, 11134351.
18. Ghosh AK, Steele R, Ray RB. MBP-1 physically associates with histone deacetylase for transcriptional repression. Biochem Biophys Res Commun 1999, 260(2):405-409. 10.1006/bbrc.1999.0921, 10403782.
19. Perconti G, Ferro A, Amato F, Rubino P, Randazzo D, Wolff T, Feo S, Giallongo A. The kelch protein NS1-BP interacts with alpha-enolase/MBP-1 and is involved in c-Myc gene transcriptional control. Biochim Biophys Acta 2007, 1773(12):1774-1785. 10.1016/j.bbamcr.2007.09.002, 17996313.
20. Hsu KW, Hsieh RH, Lee YH, Chao CH, Wu KJ, Tseng MJ, Yeh TS. The activated Notch1 receptor cooperates with alpha-enolase and MBP-1 in modulating c-myc activity. Mol Cell Biol 2008, 28(15):4829-4842. 10.1128/MCB.00175-08, 2493368, 18490439.
21. Sedoris KC, Thomas SD, Miller DM. c-myc promoter binding protein regulates the cellular response to an altered glucose concentration. Biochemistry 2007, 46(29):8659-8668. 10.1021/bi7003558, 17595061.
22. Sedoris KC, Thomas SD, Miller DM. Hypoxia induces differential translation of enolase/MBP-1. BMC Cancer 2010, 10:157. 10.1186/1471-2407-10-157, 2873388, 20412594.
23. Lo Presti M, Ferro A, Contino F, Mazzarella C, Sbacchi S, Roz E, Lupo C, Perconti G, Giallongo A, Migliorini P, et al. Myc promoter-binding protein-1 (MBP-1) is a novel potential prognostic marker in invasive ductal breast carcinoma. PLoS One 2010, 5(9):e12961. 10.1371/journal.pone.0012961, 2944896, 20886042.
24. Antona V, Cammarata G, De Gregorio L, Dragani TA, Giallongo A, Feo S. The gene encoding the transcriptional repressor BERF-1 maps to a region of conserved synteny on mouse chromosome 16 and human chromosome 3 and a related pseudogene maps to mouse chromosome 8. Cytogenet Cell Genet 1998, 83(1-2):90-92.
25. Carramusa L, Contino F, Ferro A, Minafra L, Perconti G, Giallongo A, Feo S. The PVT-1 oncogene is a Myc protein target that is overexpressed in transformed cells. J Cell Physiol 2007, 213(2):511-518. 10.1002/jcp.21133, 17503467.
26. Jenuwein T, Allis CD. Translating the histone code. Science 2001, 293(5532):1074-1080. 10.1126/science.1063127, 11498575.
27. Zhang Z, Yamashita H, Toyama T, Sugiura H, Ando Y, Mita K, Hamaguchi M, Hara Y, Kobayashi S, Iwase H. Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*. Breast Cancer Res Treat 2005, 94(1):11-16. 10.1007/s10549-005-6001-1, 16172792.
28. Suzuki J, Chen YY, Scott GK, Devries S, Chin K, Benz CC, Waldman FM, Hwang ES. Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression. Clin Cancer Res 2009, 15(9):3163-3171. 10.1158/1078-0432.CCR-08-2319, 19383825.
29. Krusche CA, Wulfing P, Kersting C, Vloet A, Bocker W, Kiesel L, Beier HM, Alfer J. Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res Treat 2005, 90(1):15-23. 10.1007/s10549-004-1668-2, 15770522.
30. Bofin AM, Ytterhus B, Martin C, O'Leary JJ, Hagmar BM. Detection and quantitation of HER-2 gene amplification and protein expression in breast carcinoma. Am J Clin Pathol 2004, 122(1):110-119. 10.1309/8A2DJFT07NE6EWHE, 15272539.
31. Vernimmen D, Gueders M, Pisvin S, Delvenne P, Winkler R. Different mechanisms are implicated in ERBB2 gene overexpression in breast and in other cancers. Br J Cancer 2003, 89(5):899-906. 10.1038/sj.bjc.6601200, 2394491, 12942124.
32. Delacroix L, Begon D, Chatel G, Jackers P, Winkler R. Distal ERBB2 promoter fragment displays specific transcriptional and nuclear binding activities in ERBB2 overexpressing breast cancer cells. DNA Cell Biol 2005, 24(9):582-594. 10.1089/dna.2005.24.582, 16153159.
33. Grooteclaes M, Pasleau F, Dijkmans H, Berzi P, Albert A, Winkler-Gol R. The 6-kilobase c-erbB2 promoter contains positive and negative regulatory elements functional in human mammary cell lines. Cancer Res 1994, 54(15):4193-4199.
34. Bates NP, Hurst HC. An intron 1 enhancer element mediates oestrogen-induced suppression of ERBB2 expression. Oncogene 1997, 15(4):473-481. 10.1038/sj.onc.1201368, 9242384.
35. Hurst HC. Update on HER-2 as a target for cancer therapy: the ERBB2 promoter and its exploitation for cancer treatment. Breast Cancer Res 2001, 3(6):395-398. 10.1186/bcr329, 138707, 11737892.
36. Begon DY, Delacroix L, Vernimmen D, Jackers P, Winkler R. Yin Yang 1 cooperates with activator protein 2 to stimulate ERBB2 gene expression in mammary cancer cells. J Biol Chem 2005, 280(26):24428-24434. 10.1074/jbc.M503790200, 15870067.
37. Birnbaum D, Sircoulomb F, Imbert J. A reason why the ERBB2 gene is amplified and not mutated in breast cancer. Cancer Cell Int 2009, 9:5. 10.1186/1475-2867-9-5, 2649042, 19226453.
38. Xing X, Wang SC, Xia W, Zou Y, Shao R, Kwong KY, Yu Z, Zhang S, Miller S, Huang L, et al. The ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis. Nat Med 2000, 6(2):189-195. 10.1038/72294, 10655108.
39. Zuo T, Wang L, Morrison C, Chang X, Zhang H, Li W, Liu Y, Wang Y, Liu X, Chan MW, et al. FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell 2007, 129(7):1275-1286. 10.1016/j.cell.2007.04.034, 1974845, 17570480.
40. Hua G, Zhu B, Rosa F, Deblon N, Adelaide J, Kahn-Perles B, Birnbaum D, Imbert J. A negative feedback regulatory loop associates the tyrosine kinase receptor ERBB2 and the transcription factor GATA4 in breast cancer cells. Mol Cancer Res 2009, 7(3):402-414. 10.1158/1541-7786.MCR-08-0175, 19276186.
41. Zupkovitz G, Tischler J, Posch M, Sadzak I, Ramsauer K, Egger G, Grausenburger R, Schweifer N, Chiocca S, Decker T, et al. Negative and positive regulation of gene expression by mouse histone deacetylase 1. Mol Cell Biol 2006, 26(21):7913-7928. 10.1128/MCB.01220-06, 1636735, 16940178.
42. Yang XJ, Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol 2008, 9(3):206-218. 10.1038/nrm2346, 2667380, 18292778.
43. Giacinti C, Giordano A. RB and cell cycle progression. Oncogene 2006, 25(38):5220-5227. 10.1038/sj.onc.1209615, 16936740.